Abstract
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have